Effects of GSK v Teva Ripple after SCOTUS Denies Cert
May 23, 2023
By: Ross Blau
Life Sciences IP Review
Axinn associate Ross Blau co-authored the Life Sciences IP Review article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."
Click here to access the publication. A subscription is required.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Informa 34th Annual Advanced EU Brussels Conference
Speaking Engagement
Antitrust
Kisaco Research Pharma and Biotech Patent Litigation Summit 2025
Speaking Engagement
Intellectual Property
GCR Live: Women in Antitrust 2025
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2025
Speaking Engagement
Litigation & Trials
ITCTLA Mock Hearing Program 2025
Speaking Engagement
Intellectual Property
ALM General Counsel Conference East 2025
Speaking Engagement
Antitrust
Axinn Recognized in Thirteen Categories of 2026 “Best Law Firms” Report
Awards & Recognitions
Antitrust
Mastering Multi-Jurisdictional Mergers: Strategies for Navigating Complex Global Antitrust Reviews
Byline Articles
Antitrust
The Government Shutdown’s Impact on Antitrust
Axinn Viewpoints
Antitrust
NAPABA Convention 2025
Sponsorship
Antitrust
